PEGylated Strontium Sulfite Nanoparticles with Spontaneously Formed Surface-Embedded Protein Corona Restrict Off-Target Distribution and Accelerate Breast Tumour-Selective Delivery of siRNA
Source abstract
Abstract
As transporters of RNAi therapeutics in preclinical and clinical studies, the application of nanoparticles is often hindered by their susceptibility to opsonin-mediated clearance, poor biological stability, ineffectual targeting, and undesirable effects on healthy cells. Prolonging the blood circulation time while minimizing the off-target distribution and associated toxicity is indispensable for the establishment of a clinically viable delivery system for therapeutic small interfering RNAs (siRNAs). Herein, we report a scalable and straightforward approach to fabricate non-toxic and biodegradable pH-responsive strontium sulfite nanoparticles (SSNs) wrapped with a hydrophilic coating material, biotinylated PEG to lessen unforeseen biological interactions. Surface functionalization of SSNs with PEG led to the generation of small and uniformly distributed particles with a significant affinity towards siRNAs and augmented internalization into breast cancer cells. A triple quadrupole liquid chromatography-mass spectrometry (LC-MS) was deployed to identify the proteins entrapped onto the SSNs, with the help of SwissProt.Mus_musculus database. The results demonstrated the reduction of opsonin proteins adsorption owing to the stealth effect of PEG. The distribution of PEGylated SSNs in mice after 4 h and 24 h of intravenous administration in breast tumour-bearing mice was found to be significantly less to the organs of the reticuloendothelial system (RES) and augmented accumulation in the tumour region. The anti-EGFR siRNA-loaded PEG-SSNs exerted a significant inhibitory effect on tumour development in the murine breast cancer model without any significant toxicity to healthy tissues. Therefore, PEGylated SSNs open up a new avenue for tumour-selective efficient delivery of siRNAs in managing breast cancer.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Petaling Jaya 47500, Malaysia
Funding
Ministry of Higher Education, Malaysia (MoHE)
References (100+)
Show source-provided references
1. RNAi-based therapeutics and tumor targeted delivery in cancer10.1016/j.addr.2022.114113 ↗
2. Uddin, M.B., Pillai, B.B., Tha, K.K., Ashaie, M., Karim, E., and Chowdhury, E.H. (2018). Carbonate Apatite Nanoparticles-Facilitated Intracellular Delivery of siRNA(s) Targeting Calcium Ion Channels Efficiently Kills Breast Cancer Cells. Toxics, 6.10.3390/toxics6030034 ↗
3. Smart pH-sensitive nanoassemblies with cleavable PEGylation for tumor targeted drug delivery10.1038/s41598-017-03111-2 ↗
4. Karim, E., Tha, K.K., Othman, I., Uddin, M.B., and Chowdhury, E.H. (2018). Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers. Pharmaceutics, 10.10.3390/pharmaceutics10020065 ↗
5. RNA interference in the clinic: Challenges and future directions10.1038/nrc2966 ↗
6. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles10.1021/mp800051m ↗
7. Therapeutic siRNA: State of the art10.1038/s41392-020-0207-x ↗
8. RNA interference-based therapy and its delivery systems10.1007/s10555-017-9717-6 ↗
9. Biomaterials in siRNA Delivery: A Comprehensive Review10.1002/adhm.201600418 ↗
10. Riley, M., and Vermerris, W. (2017). Recent Advances in Nanomaterials for Gene Delivery—A Review. Nanomaterials, 7.10.3390/nano7050094 ↗
11. Functionalization of Inorganic Nanoparticles for Bioimaging Applications10.1021/ar2000327 ↗
12. Mundekkad, D., and Cho, W.C. (2022). Nanoparticles in Clinical Translation for Cancer Therapy. Int. J. Mol. Sci., 23.10.3390/ijms23031685 ↗
13. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs
14. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology10.1016/j.addr.2013.11.009 ↗
15. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity10.1016/j.addr.2015.01.002 ↗
16. Jahan, S., Karim, E., and Chowdhury, E. (2021). Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics. Biomedicines, 9.10.3390/biomedicines9020114 ↗
17. Passive targeting of high-grade gliomas via the EPR effect: A closed path for metallic nanoparticles?10.1039/D1BM01398J ↗
18. Odyssey of a cancer nanoparticle: From injection site to site of action10.1016/j.nantod.2012.10.010 ↗
19. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles10.1073/pnas.0608582104 ↗
20. Biomolecular coronas provide the biological identity of nanosized materials10.1038/nnano.2012.207 ↗
21. Understanding biophysicochemical interactions at the nano–bio interface10.1038/nmat2442 ↗
22. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery10.2217/nnm.15.188 ↗
23. Personalized protein corona on nanoparticles and its clinical implications10.1039/C6BM00921B ↗
24. The bio-corona and its impact on nanomaterial toxicity10.1515/ejnm-2015-0018 ↗
25. Protein−Nanoparticle Interactions: Opportunities and Challenges10.1021/cr100440g ↗
26. Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of “Stealthy” Nanomaterials10.3389/fbioe.2020.00166 ↗
27. Reversible versus Irreversible Binding of Transferrin to Polystyrene Nanoparticles: Soft and Hard Corona10.1021/nn204951s ↗
28. Dell’Orco, D., Lundqvist, M., Oslakovic, C., Cedervall, T., and Linse, S. (2010). Modeling the Time Evolution of the Nanoparticle-Protein Corona in a Body Fluid. PLoS ONE, 5.10.1371/journal.pone.0010949 ↗
29. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment10.1039/C1CS15233E ↗
30. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy10.1016/j.addr.2009.03.009 ↗
31. Identification of serum proteins bound to industrial nanomaterials10.1016/j.toxlet.2011.09.009 ↗
32. Mikelez-Alonso, I., Aires, A., and Cortajarena, A.L. (2020). Cancer Nano-Immunotherapy from the Injection to the Target: The Role of Protein Corona. Int. J. Mol. Sci., 21.10.3390/ijms21020519 ↗
33. Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake10.1021/ja2084338 ↗
34. Protein corona of nanoparticles: Distinct proteins regulate the cellular uptake10.1021/acs.biomac.5b00108 ↗
35. Pre-coating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanosphere: Implications for rational design of nanoparticles10.1016/j.jconrel.2004.07.028 ↗
36. The effect of nanoparticle size, shape, and surface chemistry on biological systems10.1146/annurev-bioeng-071811-150124 ↗
37. Lynch, I., and Dawson, K.A. (2020). Protein–nanoparticle interactions. Nano-Enabled Medical Applications, Jenny Stanford Publishing, United Square.10.1201/9780429399039-8 ↗
38. Detailed Identification of Plasma Proteins Adsorbed on Copolymer Nanoparticles10.1002/anie.200700465 ↗
39. The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system10.1016/j.ijpharm.2018.10.011 ↗
40. Nanoparticles Escaping RES and Endosome: Challenges for siRNA Delivery for Cancer Therapy10.1155/2011/987530 ↗
41. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery10.1016/j.addr.2015.09.012 ↗
42. PEG—A versatile conjugating ligand for drugs and drug delivery systems10.1016/j.jconrel.2014.06.046 ↗
43. Paclitaxel Formulations: Challenges and Novel Delivery Options10.2174/1567201811666140609154949 ↗
44. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer10.1007/s00280-009-0957-1 ↗
45. Mohapatra, P., Singh, D., and Sahoo, S.K. (2021). PEGylated Nanoparticles as a Versatile Drug Delivery System. Nanoengineering of Biomaterials, Wiley Online Library.10.1002/9783527832095.ch10 ↗
46. Shedding light on zwitterionic magnetic nanoparticles: Limitations for in vivo applications10.1039/C7NR01607G ↗
47. Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy10.1016/j.jconrel.2014.12.008 ↗
48. Parameters influencing the stealthiness of colloidal drug delivery systems10.1016/j.biomaterials.2006.03.039 ↗
49. Kinetic and thermodynamic control of protein adsorption10.1073/pnas.150236197 ↗
50. PEG-modified gold nanorods with a stealth character for in vivo applications10.1016/j.jconrel.2006.06.017 ↗
51. Polymer-grafted cellulose nanocrystals as pH-responsive reversible flocculants10.1021/bm400752k ↗
52. The paradoxical functions of EGFR during breast cancer progression10.1038/sigtrans.2016.42 ↗
53. Purification and characterization of epidermal growth factor receptor/protein kinase from normal mouse liver10.1073/pnas.79.20.6237 ↗
54. Untangling the ErbB signalling network10.1038/35052073 ↗
55. Carbonate apatite nanoparticles carry siRNA(s) targeting growth factor receptor genes egfr1 and erbb2 to regress mouse breast tumor10.1080/10717544.2017.1396385 ↗
56. Role of epidermal growth factor receptor in breast cancer10.1007/s10549-012-2289-9 ↗
57. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: Promising clinical target or only a marker?10.1097/PPO.0b013e3181d24fc1 ↗
58. Karim, M.E., Shetty, J., Islam, R.A., Kaiser, A., Bakhtiar, A., and Chowdhury, E.H. (2019). Strontium sulfite: A new pH-responsive inorganic nanocarrier to deliver therapeutic siRNAs to cancer cells. Pharmaceutics, 11.10.3390/pharmaceutics11020089 ↗
59. Polymeric nanoparticles for a drug delivery system10.2174/138920021131400105 ↗
60. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles10.1016/j.biomaterials.2010.01.065 ↗
61. More Effective Nanomedicines through Particle Design10.1002/smll.201100442 ↗
62. Engineered nanoparticles interacting with cells: Size matters10.1186/1477-3155-12-5 ↗
63. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells10.1210/en.2002-220620 ↗
64. Cell Death of MCF-7 Human Breast Cancer Cells Induced by EGFR Activation in the Absence of Other Growth Factors10.4161/cc.5.16.3016 ↗
65. Kamaruzman, N.I., Tiash, S., Ashaie, M., and Chowdhury, E.H. (2018). siRNAs Targeting Growth Factor Receptor and Anti-Apoptotic Genes Synergistically Kill Breast Cancer Cells through Inhibition of MAPK and PI-3 Kinase Pathways. Biomedicines, 6.10.3390/biomedicines6030073 ↗
66. Kamaruzman, N.I., Aziz, N.A., Poh, C.L., and Chowdhury, E.H. (2019). Oncogenic Signaling in Tumorigenesis and Applications of siRNA Nanotherapeutics in Breast Cancer. Cancers, 11.10.3390/cancers11050632 ↗
67. Ashaie, M.A., Islam, R.A., Kamaruzman, N.I., Ibnat, N., Tha, K.K., and Chowdhury, E.H. (2019). Targeting Cell Adhesion Molecules via Carbonate Apatite-Mediated Delivery of Specific siRNAs to Breast Cancer Cells In Vitro and In Vivo. Pharmaceutics, 11.10.3390/pharmaceutics11070309 ↗
68. Growth factor receptors: Promising drug targets in cancer10.4103/2394-4722.163151 ↗
69. Mozar, F.S., and Chowdhury, E.H. (2017). Surface-Modification of Carbonate Apatite Nanoparticles Enhances Delivery and Cytotoxicity of Gemcitabine and Anastrozole in Breast Cancer Cells. Pharmaceutics, 9.10.3390/pharmaceutics9020021 ↗
70. Enhanced Tumor Delivery of Gemcitabine via PEG-DSPE/TPGS Mixed Micelles10.1021/mp4005904 ↗
71. A Review of Clinical Translation of Inorganic Nanoparticles10.1208/s12248-015-9780-2 ↗
72. Controlled drug delivery vehicles for cancer treatment and their performance
73. Cancer nanomedicine: Progress, challenges and opportunities10.1038/nrc.2016.108 ↗
74. The influence of size and charge of chitosan/polyglutamic acid hollow spheres on cellular internalization, viability and blood compatibility10.1016/j.biomaterials.2010.07.067 ↗
75. Regulated portals of entry into the cell10.1038/nature01451 ↗
76. Cellular Uptake, Intracellular Trafficking, and Cytotoxicity of Nanomaterials10.1002/smll.201100001 ↗
77. Cytotoxicity and cellular uptake of tri-block copolymer nanoparticles with different size and surface characteristics10.1186/1743-8977-9-11 ↗
78. Design of Asymmetric Particles Containing a Charged Interior and a Neutral Surface Charge: Comparative Study on in Vivo Circulation of Polyelectrolyte Microgels10.1021/ja503939n ↗
79. Biocompatible and colloidally stabilized mPEG-PE/calcium phosphate hybrid nanoparticles loaded with siRNAs targeting tumors10.18632/oncotarget.6428 ↗
80. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA–mPEG nanoparticles10.1016/S0378-5173(03)00224-2 ↗
81. PEGylated PRINT Nanoparticles: The Impact of PEG Density on Protein Binding, Macrophage Association, Biodistribution, and Pharmacokinetics10.1021/nl302638g ↗
82. Hossain, S., Yamamoto, H., Chowdhury, E.H., Wu, X., Hirose, H., Haque, A., Doki, Y., Mori, M., and Akaike, T. (2013). Fabrication and Intracellular Delivery of Doxorubicin/Carbonate Apatite Nanocomposites: Effect on Growth Retardation of Established Colon Tumor. PLoS ONE, 8.10.1371/journal.pone.0060428 ↗
83. Carbonate apatite-facilitated intracellular delivery of c-ROS1 siRNA sensitizes MCF-7 breast cancer cells to cisplatin and paclitaxel
84. pH-sensitive nano-crystals of carbonate apatite for smart and cell-specific transgene delivery10.1517/17425247.4.3.193 ↗
85. Bio-functional inorganic materials: An attractive branch of gene-based nano-medicine delivery for 21st century10.2174/156652305774964613 ↗
86. Designing smart nano-apatite composites: The emerging era of non-viral gene delivery
87. Regulation of MAPKs by growth factors and receptor tyrosine kinases10.1016/j.bbamcr.2007.01.002 ↗
88. Ras, PI (3) K and mTOR signalling controls tumour cell growth10.1038/nature04869 ↗
89. Intracellular delivery of p53 gene and MAPK siRNA into breast cancer cells utilizing barium salt nanoparticles
90. Mammalian integrin-targeted gene delivery: A common approach for advanced viral and non-viral vectors’
91. Intracellular delivery of ERBB2 siRNA and p53 gene synergistically inhibits the growth of established tumour in an immunocompetent mouse10.4172/1948-5956.1000256 ↗
92. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model10.1080/1061186X.2018.1525388 ↗
93. Unveiling the pitfalls of the protein corona of polymeric drug nanocarriers10.1007/s13346-020-00745-0 ↗
94. Protein corona: A new approach for nanomedicine design10.2147/IJN.S129300 ↗
95. Evaluation of nanoparticle immunotoxicity10.1038/nnano.2009.175 ↗
96. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface10.1038/nnano.2012.237 ↗
97. Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity10.1021/nl062743+ ↗
98. PEGylation of Carbonate Apatite Nanoparticles Prevents Opsonin Binding and Enhances Tumor Accumulation of Gemcitabine10.1016/j.xphs.2018.05.020 ↗
99. Serum/Plasma depletion with chicken immunoglobulin Y antibodies for proteomic analysis from multiple Mammalian species
100. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment10.1073/pnas.95.8.4607 ↗